Novartis AG ADR (NVS)vsXWELL Inc. (XWEL)
NVS
Novartis AG ADR
$160.79
-0.19%
HEALTHCARE · Cap: $303.67B
XWEL
XWELL Inc.
$0.69
-0.03%
HEALTHCARE · Cap: $6.81M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 202729% more annual revenue ($57.36B vs $28.28M). NVS leads profitability with a 17.5% profit margin vs -82.9%. NVS earns a higher WallStSmart Score of 48/100 (D+).
NVS
Hold48
out of 100
Grade: D+
XWEL
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-68.3%
Fair Value
$95.56
Current Price
$160.79
$65.23 premium
Margin of Safety
+49.5%
Fair Value
$0.78
Current Price
$0.69
$0.09 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.3%
Generating 5.6B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Trading at 8.2x book value
4.7% revenue growth
Grey zone — moderate risk
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -333.7% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bull Case : XWEL
The strongest argument for XWEL centers on Debt/Equity.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Bear Case : XWEL
The primary concerns for XWEL are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
NVS profiles as a value stock while XWEL is a turnaround play — different risk/reward profiles.
XWEL carries more volatility with a beta of 0.94 — expect wider price swings.
NVS is growing revenue faster at 4.7% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (48/100 vs 21/100), backed by strong 17.5% margins. XWEL offers better value entry with a 49.5% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →XWELL Inc.
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
XWELL Inc., a health and wellness services company, provides spa services at airports. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?